Trade GeoVax Labs, Inc. - GOVX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0364 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002096% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.2218 |
| Open | 2.2018 |
| 1-Year Change | 452.52% |
| Day's Range | 2.1518 - 2.2618 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 4, 2024 | 2.2218 | -0.0900 | -3.89% | 2.3118 | 2.3618 | 2.2018 |
| Dec 3, 2024 | 2.3318 | -0.1600 | -6.42% | 2.4918 | 2.5118 | 2.3118 |
| Dec 2, 2024 | 2.5018 | -0.1600 | -6.01% | 2.6618 | 2.7518 | 2.4618 |
| Nov 29, 2024 | 2.6218 | -0.0800 | -2.96% | 2.7018 | 2.7418 | 2.6018 |
| Nov 27, 2024 | 2.6918 | 0.0100 | 0.37% | 2.6818 | 2.7418 | 2.6018 |
| Nov 26, 2024 | 2.6818 | -0.2800 | -9.45% | 2.9618 | 3.0018 | 2.6718 |
| Nov 25, 2024 | 2.9918 | 0.0400 | 1.36% | 2.9518 | 3.1318 | 2.8918 |
| Nov 22, 2024 | 2.9318 | 0.2400 | 8.92% | 2.6918 | 3.0318 | 2.6518 |
| Nov 21, 2024 | 2.6818 | 0.0900 | 3.47% | 2.5918 | 2.7118 | 2.5718 |
| Nov 20, 2024 | 2.5918 | -0.2600 | -9.12% | 2.8518 | 2.8618 | 2.5218 |
| Nov 19, 2024 | 2.8918 | 0.0100 | 0.35% | 2.8818 | 3.0618 | 2.7818 |
| Nov 18, 2024 | 3.0018 | 0.5300 | 21.44% | 2.4718 | 3.0918 | 2.4718 |
| Nov 15, 2024 | 2.4218 | -0.1700 | -6.56% | 2.5918 | 2.5918 | 2.3618 |
| Nov 14, 2024 | 2.5818 | -0.1100 | -4.09% | 2.6918 | 2.7718 | 2.4218 |
| Nov 13, 2024 | 2.6918 | 0.0900 | 3.46% | 2.6018 | 2.7818 | 2.2718 |
| Nov 12, 2024 | 3.2018 | -0.4400 | -12.08% | 3.6418 | 3.6718 | 2.7918 |
| Nov 11, 2024 | 3.1018 | 1.0700 | 52.66% | 2.0318 | 3.2218 | 1.8918 |
| Nov 8, 2024 | 1.9318 | 0.0100 | 0.52% | 1.9218 | 1.9318 | 1.8718 |
| Nov 7, 2024 | 1.9018 | 0.0500 | 2.70% | 1.8518 | 1.9218 | 1.8418 |
| Nov 6, 2024 | 1.8218 | 0.0400 | 2.24% | 1.7818 | 1.8618 | 1.7818 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GeoVax Labs, Inc. Company profile
About Geovax Labs Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Geovax Labs Inc revenues decreased 79% to $386K. Net loss increased from $3M to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $2.4M to $15.6M (expense), General and administrative increase of 63% to $3.6M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 40M auth., 15,699,909 issd. Insiders control approx. 39.31%. IPO: NA. Private Placement: 1997, 4.4M shares @ $1. 9/06, Co. acq. by GeoVax, Inc. & name changed from Dauphin Technology, Inc. 04/10, 1-for-50 reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
1900 Lake Park Drive
Suite 380
SMYRNA
GEORGIA 30080
US
News
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024
Silver price forecast 2025 and beyond: Third party price target
Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?
16:00, 3 December 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
16:41, 28 November 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com